![Edward Samuel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Edward Samuel
Technik-/Wissenschafts-/F&E-Leiter bei ACHILLES THERAPEUTICS PLC
Profil
Edward Samuel is currently working as the SVP-Technical Operations at Achilles Therapeutics Plc since 2022.
Previously, he worked as the Director-Manufacturing at Cognate BioServices, Inc. from 2015 to 2017 and as the Manager-Cell Therapy Operations at Orchard Therapeutics Plc in 2017.
Dr. Samuel holds a doctorate degree from University College London and a graduate degree from King's College London.
Aktive Positionen von Edward Samuel
Unternehmen | Position | Beginn |
---|---|---|
ACHILLES THERAPEUTICS PLC | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2022 |
Ehemalige bekannte Positionen von Edward Samuel
Unternehmen | Position | Ende |
---|---|---|
ORCHARD THERAPEUTICS PLC | Corporate Officer/Principal | 01.12.2017 |
Cognate BioServices, Inc.
![]() Cognate BioServices, Inc. BiotechnologyHealth Technology Cognate BioServices, Inc. engages in the provision of commercialization services to regenerative medicine, cellular immunotherapy, and cell therapy companies. It offers cGMP clinical and commercial manufacturing; process and assay development and optimization; logistics, supply chain, and manufacturing support services; and clinical, regulatory, and custom services. The company was founded in 2002 and is headquartered in Memphis, TN. | Corporate Officer/Principal | 01.05.2017 |
Ausbildung von Edward Samuel
University College London | Doctorate Degree |
King's College London | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ACHILLES THERAPEUTICS PLC | Health Technology |
Private Unternehmen | 2 |
---|---|
Orchard Therapeutics Plc
![]() Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
Cognate BioServices, Inc.
![]() Cognate BioServices, Inc. BiotechnologyHealth Technology Cognate BioServices, Inc. engages in the provision of commercialization services to regenerative medicine, cellular immunotherapy, and cell therapy companies. It offers cGMP clinical and commercial manufacturing; process and assay development and optimization; logistics, supply chain, and manufacturing support services; and clinical, regulatory, and custom services. The company was founded in 2002 and is headquartered in Memphis, TN. | Health Technology |